Induction Chemotherapy Combined With Tislelizumab for Locally Advanced Squamous Cell Carcinoma of the External Auditory Canal

This study is testing whether adding an immunotherapy drug (tislelizumab) to standard chemotherapy before surgery can improve outcomes for people with advanced squamous cell carcinoma (cancer) of the ear canal. **You may be eligible if...** - You are between 18 and 80 years old - You have been diagnosed with squamous cell carcinoma of the external auditory canal (ear canal) at an advanced stage (cT3–T4) - You have not received any prior treatment for this cancer - You are in good physical condition (ECOG 0–1) - Your blood counts and organ function (liver, kidneys) are within acceptable ranges **You may NOT be eligible if...** - Your ear cancer is not squamous cell carcinoma, or is early stage or has spread to distant organs - You have previously had radiation to the head and neck - You are allergic to platinum-based or taxane chemotherapy drugs - You have a history of head and neck cancer or multiple primary cancers - You are pregnant Talk to your doctor to see if this trial is right for you.